Compact tLNP mRNA Dosing for In Vivo T-Cell Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies face limitations such as manufacturing challenges, scalability issues, variability in patient T cell potency, and safety concerns, particularly with autologous and allogeneic approaches, leading to unpredictable treatment outcomes and complications.
Innovation Solution
A compact administration regimen involving plural doses of T cell-targeted lipid nanoparticles encapsulating mRNA encoding a T cell antigen receptor, administered within 1 to 5 days of the previous dose, optionally with a conditioning biological response modifier, to enhance transfection efficiency and safety, reducing the need for larger cumulative dosages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If multiple doses of tLNP are administered within 1 to 5 days of each other, then transfection efficiency and pharmacologic effect are improved, but the complexity of administration schedule increases
Solution Approach 1:
The total dose of tLNP is divided into multiple smaller doses administered at intervals of 1 to 5 days. This segmentation approach increases transfection efficiency and pharmacologic effect compared to a single large dose, while the compact timeline (≤5-8 days) contains the complexity within a manageable framework.
Solution Approach 2:
The administration follows a periodic pattern with doses given at regular intervals of 1 to 5 days. This periodic action allows the immune system to respond to each dose sequentially, amplifying the overall therapeutic effect while maintaining a structured and predictable schedule.
2Loss of time
If a compact administration regimen with multiple doses within 1 to 5 days is used, then treatment time is reduced and earlier treatment is enabled, but the number of administration steps increases
Solution Approach 1:
The treatment is segmented into multiple doses administered within a compact timeline of 1 to 5 days. This approach accelerates treatment initiation and reduces overall treatment time compared to traditional schedules, while the limited number of steps (typically 2-4 doses) keeps the complexity manageable.
3Object-affected harmful factors
If smaller individual dosages are used in a compact regimen, then safety is improved and toxicity is reduced, but the cumulative dosage requirement increases
Solution Approach 1:
The total therapeutic dosage is segmented into multiple smaller individual doses administered at 1 to 5 day intervals. This segmentation reduces peak toxicity levels associated with large single doses, while the cumulative effect over the compact timeline achieves the desired therapeutic outcome with improved safety profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves greater transfection efficiency, pharmacologic effect, and safety by generating more active T cells in vivo, avoiding manufacturing complexities and lymphodepletion-associated toxicities, allowing earlier treatment and reducing toxicity risks.
Implementation Method 1
T cell-targeted lipid nanoparticle (tLNP) encapsulating mRNA encoding a T cell antigen receptor
Implementation Method 2
mRNA encoding a T cell antigen receptor... generating more active T cells in vivo
Data Source
AI summary
This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.